Introduction

In a closely contested pharmaceutical patent dispute, the Delaware District Court delivered a split judgment in Otsuka Pharmaceutical Co., Ltd. v. Lupin Limited et al. (Case No. 1:21-cv-00900), closing one of the more nuanced tolvaptan patent infringement cases in recent ANDA litigation history. Filed in June 2021 and resolved in August 2024, the case produced neither a clean win nor a decisive loss for either party — an outcome that carries significant strategic weight across the pharmaceutical IP landscape.

At the center of the dispute were Otsuka’s branded JYNARQUE® tablets and Lupin’s proposed generic tolvaptan formulations. The court ultimately ruled in favor of Lupin on infringement and invalidity of one patent, while siding with Otsuka on validity and enforceability of another. For patent attorneys navigating Hatch-Waxman litigation, IP professionals monitoring specialty pharmaceutical portfolios, and R&D leaders managing freedom-to-operate risk, this mixed judgment offers a rich set of lessons on claim drafting, obviousness doctrine, and multi-patent assertion strategy.

Case Overview

The Parties

The Patents at Issue

Three U.S. patents were identified in the litigation:

• • U.S. Patent No. 8,273,735 (App. No. 12/064,178) — Claims 7, 8, and 10 were at issue, covering pharmaceutical compositions and formulation-related claims tied to tolvaptan.
• • U.S. Patent No. 8,501,730 (App. No. 13/474,521) — Claims 1, 2, 4, and 5 were contested, relating to additional compound or method claims for tolvaptan use.
• • U.S. Patent No. 10,905,694 (App. No. 12/665,642) — Listed among patents involved, though the final judgment specifically addressed the ‘735 and ‘730 patents on the merits.

The Accused Products

Lupin’s ANDA Products — generic tolvaptan tablets in five dosage strengths (15, 30, 45, 60, and 90 mg) — were alleged to infringe Otsuka’s listed patents upon commercial manufacture, importation, offer for sale, or sale in the United States.

Legal Representation

Otsuka was represented by Jack B. Blumenfeld of Morris, Nichols, Arsht & Tunnell LLP, a Delaware litigation powerhouse with an extensive pharmaceutical patent docket. Lupin retained Alexandra M. Ewing of Richards, Layton & Finger, PA, another elite Delaware IP firm. The presence of both firms signals the high-stakes, technically complex nature of this Hatch-Waxman dispute.

The Verdict & Legal Analysis

Outcome: A Mixed Judgment

The court’s final judgment — classified as a Mixed Judgment — produced distinct outcomes across the two principal patents:

U.S. Patent No. 8,273,735 — Judgment for Lupin:

• • The court ruled that Lupin’s ANDA Products do not infringe Claims 7, 8, and 10.
• • The court further ruled Claims 7, 8, and 10 invalid under 35 U.S.C. § 103 (obviousness) on Lupin’s counterclaims.

U.S. Patent No. 8,501,730 — Partially for Otsuka:

• • The court ruled that Lupin’s ANDA Products do not infringe Claims 1, 2, 4, and 5.
• • However, the court ruled in Otsuka’s favor on Lupin’s invalidity counterclaims — finding Claims 1, 2, 4, and 5 not invalid under § 103.
• • Otsuka also prevailed on inequitable conduct counterclaims for both patents — the court rejected Lupin’s allegations of unenforceability based on inequitable conduct before the USPTO.

No damages were awarded given the non-infringement findings. No injunctive relief was granted.

Verdict Cause Analysis

Obviousness Under § 103 — The Decisive Legal Question

The central battleground was obviousness doctrine. For the ‘735 patent, Lupin successfully argued that Claims 7, 8, and 10 were rendered obvious by prior art — a significant victory that invalidated these claims entirely and removed them as future enforcement tools. The court’s Trial Opinion, referenced but not reproduced in the judgment, presumably addressed the scope of prior art, motivation to combine, and reasonable expectation of success — the standard Graham v. John Deere framework.

For the ‘730 patent, Otsuka successfully defended validity, demonstrating that Claims 1, 2, 4, and 5 were not obvious over the prior art. This is a meaningful prosecution and enforcement asset: the ‘730 patent survives with its claims intact, even though infringement was not established against this particular ANDA product.

Non-Infringement Findings

The non-infringement rulings across both patents suggest that Lupin’s ANDA formulation fell outside the literal scope of the asserted claims — potentially through formulation differences, dosage-specific limitations, or claim construction outcomes favoring Lupin. The absence of a doctrine of equivalents finding (or lack of data suggesting one was argued successfully) implies a relatively defined claim boundary.

Inequitable Conduct — Otsuka’s Clean Win

Lupin’s counterclaims of unenforceability based on inequitable conduct were rejected in full for both patents. This outcome reinforces the high bar defendants must clear under Therasense, Inc. v. Becton, Dickinson & Co. — demonstrating both but-for materiality and specific intent to deceive the USPTO. Otsuka’s prosecution integrity withstood scrutiny, preserving the enforceability of both patents against future ANDA filers.

Legal Significance

This case illustrates the layered complexity of multi-patent ANDA litigation. A defendant can simultaneously defeat infringement claims, invalidate one patent, fail to invalidate another, and lose on inequitable conduct — all in the same proceeding. The survival of the ‘730 patent’s validity positions Otsuka to assert it in future Paragraph IV disputes, potentially with stronger claim construction arguments tailored against different ANDA formulations.

Strategic Takeaways

For Patent Holders: Layered patent portfolios across multiple application numbers provide enforcement resilience. Even when one patent falls on obviousness grounds, surviving patents with upheld validity retain litigation value.

For Generic Defendants: Succeeding on non-infringement while also pursuing invalidity creates redundant protection. The ‘735 invalidation removes a future threat permanently, regardless of the non-infringement finding on the ‘730.

For R&D Teams: ANDA filers should conduct rigorous freedom-to-operate analyses covering not just infringement but validity of each listed patent — outcomes here show that each patent in a portfolio can yield entirely different results.